Skip to main content

Table 4 The mean changes in clinical indicators from baseline at weeks 12 and 24 in both ACR50 and ACR70 negative groups and ACR50 and ACR70 positive groups

From: Matrix metalloproteinase-3 and the 7-joint ultrasound score in the assessment of disease activity and therapeutic efficacy in patients with moderate to severe rheumatoid arthritis

 

ACR50

ACR70

Negative

Positive

Negative

Positive

ΔDAS28

W12

2.304 ± 1.626

2.688 ± 0.996

2.583 ± 1.257

2.51 ± 1.255

W24

2.536 ± 1.598

2.857 ± 0.962

2.591 ± 1.314

2.898 ± 1.099

ΔMMP-3

W12

84.914 ± 32.938

122.599 ± 149.654

102.92 ± 66.121

133.385 ± 182.232

W24

69.139 ± 33.066

124.365 ± 107.828**

76.244 ± 49.253

127.828 ± 220.685**

ΔUS7

W12

1.143 ± 1.215

9.154 ± 8.061***

1.75 ± 1.658

13.25 ± 7.704***

W24

0.857 ± 1.676

9.692 ± 7.836***

1.5 ± 2.224

11.7 ± 7.775***

ΔCRP

W12

3.571 ± 4.315

8.769 ± 10.109

6.250 ± 7.689

8.000 ± 10.664

W24

3.00 ± 5.888

7.385 ± 11.507

5.600 ± 9.582

6.100 ± 16.032

ΔAnti-CCP

W12

68.01 ± 166.238

69.32 ± 149.09

58.1 ± 143.488

72.145 ± 108.321

W24

75.47 ± 158.87

77.35 ± 127.76

69.68 ± 122.58

77.65 ± 148.53

ΔHAQ

W12

8.429 ± 8.904

10.385 ± 13.556

7.33 ± 8.283

13.250 ± 15.926

W24

9.429 ± 9.502

9.231 ± 8.757

8.0 ± 9.534

10.6 ± 8.235

ΔESR

W12

28.714 ± 22.134

31.615 ± 21.964

35.41 ± 20.291

32.75 ± 21.446

W24

25.429 ± 19.68

22.231 ± 28.94

27.8 ± 20.065

18.90 ± 30.552

  1. The Δ symbol represents changes from baseline
  2. ACR50 American College of Rheumatology 50% response, ACR70 ACR 70% response, CCP cyclic citrullinated peptide, CRP C-reactive protein, DAS28 disease activity score in 28 joints, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, MMP-3 matrix metalloproteinase-3, US7 7-joint ultrasound score
  3. Compared with the negative group, ***p < 0.001, **p < 0.01, *p < 0.05